Date: 2015-10-19
Type of information: Collaboration agreement
Compound:
Company: Janssen Biotech, a J&J company (USA - NJ) Nuevolution (Denmark)
Therapeutic area: Cancer - Oncology - Infectious diseases - Inflammatory diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On October 19, 2015, Nuevolution announced that it has entered into collaboration with Janssen Biotech, using Nuevolution’s proprietary Chemetics® drug discovery platform. The collaboration was facilitated by Johnson & Johnson Innovation, in partnership with Janssen Discovery Sciences. Nuevolution, a privately held Copenhagen-based biotechnology company is applying its propriety drug discovery platform to the generation of novel small molecule therapeutics. This collaboration will be a multi-target collaboration with Janssen. The collaboration will focus on the discovery and development of new medical entities for the treatment of oncological, infectious and inflammatory diseases. Within the framework of the collaboration, Nuevolution will apply its drug discovery platform Chemetics® to discover and advance drug candidates against drug targets of interest to Janssen.
Financial terms: Under the terms of the agreement, Nuevolution will receive an upfront payment, research funding and would be eligible to milestone payments upon achievement of specified research, development and commercial milestones. In addition, Nuevolution would be entitled to receive certain royalty payments on net-sale of products that may be commercialized as a result of the collaboration.
Latest news:
